Abstract: An ex vivo malignant tumor tissue sample is cleaned, comminuted, suspended in culture medium, subjected to a treatment with collagenase and the collagenase decomposition product is centrifuged. The pellet obtained is re-suspended in culture medium by an absorption instrument, is absorbed and returned several times and transferred to a culture vessel. The re-suspension thus obtained is analyzed under a microscope with phase optics for cell aggregates, which, due to the phenotypic appearance thereof, are identifiable as an aggregate of malignant cells or as an aggregate of endothelial cells or as an aggregate of fibroblasts, and the identified cell aggregates are separated.

Abstract: The method comprises the steps wherein the tumour cells from a tumor tissue sample previously taken from a particular patient are incubated ex vivo with the active agent concerned and the IC50 value thereof for these cells is determined; wherein the same patient is treated with this active agent in accordance with evidence-based therapy rules; wherein the therapy outcome is documented and classified; and wherein the documentation and/or classification of the therapy outcome obtained is assigned to the IC50 value determined ex vivo.

Abstract: An ex vivo malignant tumor tissue sample is cleaned, comminuted, suspended in culture medium, subjected to a treatment with collagenase and the collagenase decomposition product is centrifuged. The pellet obtained is re-suspended in culture medium by an absorption instrument, is absorbed and returned several times and transferred to a culture vessel. The re-suspension thus obtained is analyzed under a microscope with phase optics for cell aggregates, which, due to the phenotypic appearance thereof, are identifiable as an aggregate of malignant cells or as an aggregate of endothelial cells or as an aggregate of fibroblasts, and the identified cell aggregates are separated.